Mankind Pharma, India’s fourth largest pharmaceutical company, has reported Q3 FY 24 PAT (Profit After Tax) of Rs. 460 crore, a growth of 55% YoY growth.   

Revenue from Operations stood at Rs. 2,607 crore, 25% YoY growth. Domestic revenue at Rs. 2,400 crore, 20% YoY growth and export revenue at Rs. 207 crore, 118% YoY growth.

Rajeev Juneja, Vice Chairman & Managing Director said, “We are delighted to announce strong Q3 results with domestic growth of 20% YoY led by robust growth in chronic, recovery in anti-infectives and strong growth in modern trade and hospital sales. Our top 5 therapeutics by sales have outperformed the IPM by 1.5x. We have increased our market share in 18 out of the top 20 brands on both QoQ and YoY basis. These have resulted in a robust EBITDA growth of 39% YoY and PAT growth of 55% YoY in Q3. We continue to focus on improving cash flow from operations and optimising our working capital cycle.”

Domestic Business witnessed a strong growth of 20% YoY during Q3 FY24 primarily driven by out-performance in chronic therapies (1.5x to IPM), recovery in anti-infectives (13.8% YoY vs 9.5% in IPM), further bolstered by strong growth in modern trade and hospital sales.

Consumer Healthcare segment revenue declined during the quarter due to initiatives taken in the last quarter towards optimization of channel inventory; implementation of IT tools to facilitate stockist consolidation. Exports business witnessed a growth of 118% YoY in Q3FY24 aided by certain one-off opportunities in the US.